Condition
Non-Small-Cell Lung
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownSymbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCNCT07489066 · 2026-06-30
RECRUITINGA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaNCT07316062 · 2026-04-29
RECRUITINGPhase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655 · 2026-04-08
RECRUITINGJIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI FailureNCT07798921 · 2026-09-28
NOT_YET_RECRUITINGA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentNCT07567352 · 2026-05-01
ACTIVE_NOT_RECRUITINGSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · 2022-08-03
ACTIVE_NOT_RECRUITINGStudy of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerNCT04362072 · 2020-09-29
COMPLETEDA Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT03952403 · 2019-12-02
UNKNOWNAnlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerNCT03766490 · 2019-03-30
UNKNOWNPhase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line TherapyNCT03626545 · 2019-01-23
TERMINATEDApatinib in the Treatment of Patients With EGFR T790M-Negative NSCLCNCT03389256 · 2018-12-30
UNKNOWNA Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)NCT03456063 · 2018-04-24
COMPLETEDA 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).NCT00863746 · 2009-04-01
COMPLETEDCommon interventions
CarboplatinDRUG3PemetrexedDRUG3CisplatinDRUG2lorlatinibDRUG2Anlotinib HydrochlorideDRUG1ApatinibDRUG1Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyDRUG1CanakinumabDRUG1Chemotherapy Regimen 1DRUG1Chemotherapy Regimen 2DRUG1DocetaxelDRUG1EGFR-TKIDRUG1GefitinibDRUG1GemcitabineDRUG1HLX04, a bevacizumab biosimilarDRUG1HLX10, an engineered anti-PD-1 antibodyDRUG1IcotinibDRUG1JIN-A02 in Combination with AmivantamabDRUG1Nab-paclitaxelDRUG1OsimertinibDRUG1PF-08046033DRUG1PF-08634404BIOLOGICAL1PlaceboDRUG1PlaceboOTHER1Placebo ComparatorDRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING3
UNKNOWN3
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE35
PHASE12
PHASE22
NA1
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.